Oneness Biotech is focused on developing innovative therapies to address unmet medical needs, particularly in the fields of dermatology and immunology. Their lead product, ON101 (FESPIXON®), is a first-in-class drug designed to enhance the healing of chronic wounds, specifically diabetic foot ulcers, by targeting macrophage subsets. This drug has shown superior efficacy compared to standard care in Phase 3 clinical trials conducted across the US, Taiwan, and China, and has been granted Fast Track designation by the US FDA. Other notable products in their pipeline include FB825, an antibody targeting IgE B cells for allergic diseases, and FB704A, a monoclonal antibody that neutralizes IL-6 to treat severe asthma and chronic kidney disease.

In addition to these, Oneness Biotech is developing OB318 for hepatocellular carcinoma, SNS812 as a siRNA treatment for COVID-19, and SNS851 aimed at weight loss and metabolic improvement. The company emphasizes a robust research and development framework that allows it to compete with international pharmaceutical firms, leveraging scientific innovation to maximize the value of its products. Their commitment to integrity and transparency is reflected in their corporate governance practices and regular communication with investors, including quarterly updates and annual ESG reports.

Taiwan

Oneness Biotech is dedicated to fulfilling unmet medical needs by developing new drugs focused on chronic disorders in dermatology and immunology

Oneness Biotech

Company Details